Teamwork Financial Advisors LLC Boosts Stock Position in Novo Nordisk A/S $NVO

Teamwork Financial Advisors LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO) by 60.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 29,546 shares of the company’s stock after acquiring an additional 11,158 shares during the quarter. Teamwork Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,640,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. NewSquare Capital LLC increased its position in shares of Novo Nordisk A/S by 174.1% during the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares in the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $37,000. State of Wyoming purchased a new position in Novo Nordisk A/S during the 1st quarter worth approximately $38,000. Maseco LLP acquired a new position in Novo Nordisk A/S during the second quarter worth approximately $39,000. Finally, Copeland Capital Management LLC lifted its stake in Novo Nordisk A/S by 47.3% in the second quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after buying an additional 186 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 0.3%

NVO stock opened at $47.61 on Friday. The stock has a market capitalization of $212.59 billion, a PE ratio of 13.84 and a beta of 0.67. The company has a fifty day moving average of $50.01 and a 200-day moving average of $57.86. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $104.75.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The business had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on NVO shares. Morgan Stanley reaffirmed an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 25th. Rothschild Redb upgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Wednesday, December 3rd. Finally, Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.